{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45","upperLimit":"69","value":"58"},{"groupId":"OG001","lowerLimit":"25","upperLimit":"71","value":"50"},{"groupId":"OG002","lowerLimit":"45","upperLimit":"62","value":"54"},{"groupId":"OG003","lowerLimit":"6","upperLimit":"84","value":"50"},{"groupId":"OG004","lowerLimit":"23","upperLimit":"52","value":"38"},{"groupId":"OG005","lowerLimit":"0.1","upperLimit":"91","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"130"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"40"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"description":"Overall survival (OS) was measured from peripheral stem cell infusion to death from any cause. It was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula. Participants were followed up to 2 years after transplant and Kaplan-Meier survival analysis was used to generate the two-year Overall Survival estimate presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients undergo total body irradiation (TBI) on days -7 to -4 and receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1.\n\ncyclophosphamide\n\ncyclosporine\n\nmethotrexate\n\nmycophenolate mofetil\n\nsirolimus\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation\n\ntotal-body irradiation","id":"OG000","title":"Regimen I"},{"description":"Patients receive busulfan IV over 2 hours once on day -8 and then every 6 hours on days -7 to -4. Patients also receive cyclophosphamide IV on days -3 and -2.\n\nbusulfan\n\ncyclophosphamide\n\ncyclosporine\n\nmethotrexate\n\nmycophenolate mofetil\n\nsirolimus\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation","id":"OG001","title":"Regimen II"},{"description":"Patients undergo TBI on days -7 to -4 and receive etoposide IV on day -3.\n\ncyclosporine\n\netoposide\n\nmethotrexate\n\nmycophenolate mofetil\n\nsirolimus\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation\n\ntotal-body irradiation","id":"OG002","title":"Regimen III"},{"description":"Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3 and melphalan IV on day -2.\n\ncyclosporine\n\nfludarabine phosphate\n\nmelphalan\n\nmethotrexate\n\nmycophenolate mofetil\n\nsirolimus\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation","id":"OG003","title":"Regimen IV"},{"description":"Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo TBI on day 0.\n\ncyclosporine\n\nfludarabine phosphate\n\nmethotrexate\n\nmycophenolate mofetil\n\nsirolimus\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation\n\ntotal-body irradiation","id":"OG004","title":"Regimen V"},{"description":"Patients receive busulfan IV over 3 hours and fludarabine phosphate IV over 30 minutes on days -5 to -2.\n\nbusulfan\n\ncyclosporine\n\nfludarabine phosphate\n\nmethotrexate\n\nmycophenolate mofetil\n\nsirolimus\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation","id":"OG005","title":"Regimen VI"}],"paramType":"NUMBER","populationDescription":"1 subject in Regimen II did not have transplant.","reportingStatus":"POSTED","timeFrame":"Up to 2 years post transplant","title":"Two-year Overall Survival","type":"SECONDARY","unitOfMeasure":"percentage of survival probability"}